Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Quinagolide (Norprolac®)
Raloxifene tablets	TA160 - Osteoporosis - secondary prevention including strontium ranelate TA161 - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Rasagiline		ESCA
Riboflavin		Specialist recommendation - inherited metabolic disease.
Rifampicin
Riluzole tablets	TA20 - Guidance on the use of Riluzone (Rilutek) for the treatment of Motor Neurone Disease	ESCA
Risperidone liquid		ESCA
Risperidone tablets		ESCA
Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome TA256 - Atrial fibrillation (stroke prevention) - Rivaroxaban TA261 - Venous thromboembolism (treatment and long-term secondary prevention) - Rivaroxaban TA287 - Pulmonary embolism and recurrent venous thromboembolism TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	Amber - specialist initation following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants Amber - specialist initation for the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD Amber - specialist initiation for preventing adverse outcomes after acute management of ACS use in line with NICE TA335. Initiation/recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD
Rivastigmine capsules	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.